NAUT

Nautilus Biotechnology Inc

Add to Watchlist

Advanced Chart

0.788

+0.037(4.928%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.7999

Open

0.760

VWAP

0.77

Vol

350.92K

Mkt Cap

99.48M

Low

0.7322

Amount

268.74K

EV/EBITDA(TTM)

Total Shares

125.27M

-53.04M

EV/OCF(TTM)

P/S(TTM)

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

3 Analyst Rating

249.16% Upside

Wall Street analysts forecast NAUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAUT is 2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

249.16% Upside

Current: 0.788

Low

2.50

Averages

2.75

High

3.00

249.16% Upside

Current: 0.788

Low

2.50

Averages

2.75

High

3.00

Goldman Sachs

Matthew Sykes

Hold

Strong Sell

Downgrades

$2.25 → $1.75

2024-12-05

Reason

Goldman Sachs

Matthew Sykes

Price Target

$2.25 → $1.75

2024-12-05

Downgrades

Hold

Strong Sell

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Nautilus Biotechnology Inc (NAUT.O) is -1.21, compared to its 5-year average forward P/E of -6.48. For a more detailed relative valuation and DCF analysis to assess Nautilus Biotechnology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.48

Current PE

-1.21

Overvalued PE

0.59

Undervalued PE

-13.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.60

Current EV/EBITDA

0.34

Overvalued EV/EBITDA

1.34

Undervalued EV/EBITDA

-6.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

529.56

Current PS

0.00

Overvalued PS

1668.55

Undervalued PS

-609.44